These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 1722967)

  • 21. Cocaine-Induced raynaud's phenomenon and ischaemic finger necrosis.
    Balbir-Gurman A; Braun-Moscovici Y; Nahir AM
    Clin Rheumatol; 2001; 20(5):376-8. PubMed ID: 11642523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
    Mittag M; Beckheinrich P; Haustein UF
    Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
    Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
    Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
    Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Raynaud's phenomenon in children].
    Quartier P
    Arch Pediatr; 2004 Jan; 11(1):74-7. PubMed ID: 14700771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
    Keller J; Kaltenecker A; Schricker KT; Krais T; Schönberger A; Gevatter M; Hornstein OP
    Dtsch Med Wochenschr; 1984 Sep; 109(38):1433-8. PubMed ID: 6383760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
    Mohrland JS; Porter JM; Smith EA; Belch J; Simms MH
    Ann Rheum Dis; 1985 Nov; 44(11):754-60. PubMed ID: 3904643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thromboangiitis obliterans: a rare cause of a reversible Raynaud's phenomenon.
    Noël B; Krayenbühl B; Cerottini JP; Guggisberg D; Buxtorf K; Pires A; Panizzon RG
    Dermatology; 2000; 200(4):363-5. PubMed ID: 10894979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients].
    Ben Salem T; Tougorti M; Bziouech S; Lamloum M; Khanfir M; Ben Ghorbel I; Houman MH
    J Med Vasc; 2018 Feb; 43(1):29-35. PubMed ID: 29425538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).
    Fraticelli P; Martino GP; Murri M; Mattioli M; Gabrielli A
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):173-178. PubMed ID: 28869415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.
    Kahan A; Weber S; Amor B; Menkes CJ; Hodara M; Degeorges M
    Int Angiol; 1985; 4(2):221-3. PubMed ID: 3831143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases.
    Priollet P; Vayssairat M; Housset E
    Am J Med; 1987 Sep; 83(3):494-8. PubMed ID: 3661586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is iloprost effective in secondary Raynaud's phenomenon?
    Lustig N; Rada G
    Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of vasculitic leg ulcers in connective tissue disease with iloprost.
    Veale DJ; Muir AH; Morley KD; Belch JJ
    Clin Rheumatol; 1995 Mar; 14(2):187-90. PubMed ID: 7540526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon.
    Lamprecht P; Schnabel A; Gross WL
    Br J Rheumatol; 1998 Jun; 37(6):703-4. PubMed ID: 9667634
    [No Abstract]   [Full Text] [Related]  

  • 38. Nailfold capillaroscopy in the screening and diagnosis of Raynaud's phenomenon.
    Mannarino E; Pasqualini L; Fedeli F; Scricciolo V; Innocente S
    Angiology; 1994 Jan; 45(1):37-42. PubMed ID: 8285382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Raynaud's phenomenon, disease or syndrome?].
    Fiessinger JN
    Rev Prat; 2011 Sep; 61(7):899-903. PubMed ID: 22039719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.